A genome-wide meta-analysis of nodular sclerosing Hodgkin lymphoma identifies risk loci at 6p21.32

Blood

Volumn 119, Issue 2, 2012, Pages 469-475

  Cozen, Wendy ^a,b   Li, Dalin ^a   Best, Timothy ^c   Van Den Berg, David J ^a,b   Gourraud, Pierre Antoine ^d   Cortessis, Victoria K ^a,b   Skol, Andrew D ^e   Mack, Thomas M ^a,b   Glaser, Sally L ^f,g   Weiss, Lawrence M ^h   Nathwani, Bharat N ^b,i   Bhatia, Smita ^h   Schumacher, Fredrick R ^a,b   Edlund, Christopher K ^a   Hwang, Amie E ^a   Slager, Susan L ^j   Fredericksen, Zachary S ^j   Strong, Louise C ^k   Habermann, Thomas M ^j   Link, Brian K ^l   Cerhan, James R ^j   Robison, Leslie L ^m   Conti, David V ^a,b   Onel, Kenan ^c,n   more..

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^b UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^c UNIVERSITY OF CHICAGO   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e UNIVERSITY OF CHICAGO   (United States)

^f CANCER PREVENTION INSTITUTE OF CALIFORNIA   (United States)

^g STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^h CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

ⁱ CEDARS SINAI MEDICAL CENTER   (United States)

^j MAYO CLINIC COLLEGE OF MEDICINE   (United States)

^k UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^l UNIVERSITY OF IOWA   (United States)

^m ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

ⁿ UNIVERSITY OF CHICAGO   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

HLA DRB1 ANTIGEN;

ADOLESCENT; ADULT; ARTICLE; CANCER RISK; CANCER SUSCEPTIBILITY; CHROMOSOME 6P; CONTROLLED STUDY; FEMALE; GENETIC ASSOCIATION; GENETIC RISK; GENETIC SUSCEPTIBILITY; HAPLOTYPE; HUMAN; MAJOR CLINICAL STUDY; MALE; NODULAR SCLEROSIS HODGKIN LYMPHOMA; PRIORITY JOURNAL; RISK ASSESSMENT; SINGLE NUCLEOTIDE POLYMORPHISM;

EID: 84862910604     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2011-03-343921     Document Type: Article

References (40)

1. Mani H, Jaffe ES. Hodgkin lymphoma: an update on its biology with newer insights into classification. Clin Lymphoma Myeloma. 2009;9(3):206-216.
2. Curado MP, Edwards B, Shin HR, et al. Cancer incidence in five continents. Volume IX. IARC scientific publication number 160. Lyon, France: World Health Organization Publications; 2009.
3. Cozen W, Katz J, Mack TM. Hodgkin's disease varies by cell type in Los Angeles. Cancer Epidemiol Biomarkers Prev. 1992;1(4):261-268.
4. Mueller NE, Grufferman S. Hodgkin lymphoma. In: Schottenfeld D, Fraumeni JF Jr, eds. Cancer Epidemiology and Prevention. New York, NY: Oxford University Press; 2006:872-897.
5. Hjalgrim H, Askling J, Rostgaard K, et al. Characteristics of Hodgkin's lymphoma after infectious mononucleosis. N Engl J Med. 2003;349(14):1324-1332. (Pubitemid 37186210)
6. Cozen W, Hamilton AS, Zhao P, et al. A protective role for early childhood exposures and young adult Hodgkin lymphoma. Blood. 2009;114(19):4014-4020.
7. Glaser SL, Gulley ML, Clarke CA, et al. Racial/ethnic variation in EBV-positive classical Hodgkin lymphoma in California populations. Int J Cancer. 2008;123(7):1499-1507.
8. Birgersdotter A, Baumforth KRN, Porwit A, et al. Inflammation and tissue repair markers distinguish the nodular sclerosis and mixed cellularity subtypes of classical Hodgkin's lymphoma. Br J Cancer. 2009;101(8):1393-1401.
9. Mack TM, Cozen W, Shibata DK, et al. Concordance for Hodgkin's disease in identical twins suggests genetic susceptibility to the young-adult form of the disease. N Engl J Med. 1995;332(7):413-418.
10. Harty LC, Lin AY, Goldstein AM, et al. HLA-DR, HLA-DQ, and TAP genes in familial Hodgkin disease. Blood. 2002;99(2):690-693. (Pubitemid 34533109)
11. Staratschek-Jox A, Shugart YY, Strom SS, Nagler A, Taylor GM. Genetic susceptibility to Hodgkin's lymphoma and to secondary cancer: workshop report. Ann Oncol. 2002;13(suppl 1):30-33. (Pubitemid 34567398)
12. Klitz W, Aldrich C, Fildes N, Horning S, Begovich A. Localization of predisposition to Hodgkin's disease in the HLA class II region. Am J Hum Genet. 1994;54(3):497-505. (Pubitemid 24068231)
13. Cozen W, Gill PS, Ingles SA et al. IL-6 levels and genotype are associated with risk of young adult hodgkin lymphoma. Blood. 2004;103(8):3216-3221. (Pubitemid 38451701)
14. Cordano P, Lake A, Shield L et al. Effect of IL-6 promoter polymorphism on incidence and outcome in Hodgkin's lymphoma. Br J Haematol. 2005;128(4):493-495. (Pubitemid 40283166)
15. Nieters A, Beckmann L, Deeg E, Becker N. Gene polymorphisms in Toll-like receptors, interleukin-10, and interleukin-10 receptor alpha and lymphoma risk. Genes Immun. 2006;7(8):615-624. (Pubitemid 46242365)
16. Cozen W, Gill PS, Salam MT, et al. Interleukin-2, interleukin-12 and interferon-gamma levels and risk of young adult Hodgkin lymphoma. Blood. 2008;111(7):3377-3382.
17. Broderick P, Cunningham D, Vijayakrishnan J, et al. IRF4 polymorphism rs872071 and risk of Hodgkin lymphoma. Br J Haematol. 2010;148(3):413-415.
18. Mollaki V, Georgiadis T, Tassidou A, et al. Polymorphisms and haplotypes in TLR9 and MYD88 are associated with the development of Hodgkin's lymphoma: a candidate-gene association study. J Hum Genet. 2009;54(11):655-659.
19. Salipante SJ, Mealiffe ME, Wechsler J, et al. Mutations in a gene encoding a midbody kelch protein in familial and sporadic classical Hodgkin lymphoma lead to binucleated cells. Proc Natl Acad Sci U S A. 2009;106(35):14920-14925.
20. Enciso-Mora V, Broderick P, Ma Y, et al. A genome-wide association study of Hodgkin's lymphoma identifies new susceptibility loci at 2p15.1 (REL), 8q24.21 and 10p14 (GATA3). Nat Genet. 2010;42(12):1126-1230.
21. Cockburn MG, Hamilton AS, Zadnick J, Cozen W, Mack TM. Development and representativeness of a large population-based cohort of native California twins. Twin Res. 2001;4(4):242-250. (Pubitemid 34151416)
22. Mack TM, Deapen D, Hamilton AS. Representativeness of a roster of volunteer North American twins with chronic disease. Twin Res. 2000;3(1):33-42. (Pubitemid 30190662)
23. Hunter DJ, Kraft P, Jacobs KB, et al. A genome-wide association study identifies alleles in FGFR2 associated with risk of sporadic postmenopausal breast cancer. Nat Genet. 2007;39(7):870-874. (Pubitemid 47014500)
24. Mailman MD, Feolo M, Jin Y, et al. The NCBI dbGaP Database of Genotypes and Phenotypes. Nat Genet. 2007;39(7):1181-1186. (Pubitemid 47482671)
25. Robison LL, Armstrong GT, Boice JD, et al. The Childhood Cancer Survivor Study: A National Cancer Institute-supported resource for outcome and intervention research. J Clin Oncol. 2009;27(14):2308-2318.
26. GAIN Collaborative Research Group; Manolio TA, Rodriguez LL, Brooks L, et al. New models of collaboration in genome-wide association studies: the Genetic Association Information Network. Nat Genet. 2007;39(9):1045-1451.
27. Price AL, Patterson NJ, Plenge RM, Weinblatt ME, Shadick NA, Reich D. Principal components analysis corrects for stratification in genome-wide association studies. Nat Genet. 2006;38(8):904-909. (Pubitemid 44141658)
28. Gourraud PA, Génin E, Cambon-Thomsen A. Handling missing values in population data: consequences for maximum likelihood estimation of haplotype frequencies. Eur J Hum Genet. 2004;12(10):805-812. (Pubitemid 39406064)
29. Devlin B, Roeder K. Genomic control for associations. Biometrics. 1999;55(4):997-1004.
30. The MHC Sequencing Consortium. Complete sequence and gene map of a human major histocompatibility complex. Nature. 1999;401(6756):921-923.
31. de Bakker PIW, McVean G, Sabeti PC, et al. A high-resolution HLA and SNP haplotype map for disease association studies in the extended human MHC. Nat Genet. 2006;38(10):1166-1172. (Pubitemid 44470362)
32. Huang X, Kushekhar K, Nolte I, et al. Multiple HLA class I and II associations in classical Hodgkin lymphoma and EBV status defined subgroups. Blood. 2011;118(19):5211-5217.
33. Conde L, Halperin E, Akers NK, et al. Genome-wide association study of follicular lymphoma identifies a risk locus at 6p21.32. Nat Genet. 2010;42(8):661-664.
34. Alcoceba M, Marin L, Balanzategui A, et al. The presence of DRB1*01 allele in multiple myeloma patients is associated with an indolent disease. Tissue Antigens. 2008;71(6):548-551. (Pubitemid 351697251)
35. Conde L, Bracci PM, Halperin E, Skibola CF. A search for overlapping genetic susceptibility loci between non-Hodgkin lymphoma and autoimmune diseases. Genomics. 2011;98(1):9-14.
36. Jones EY, Fugger L, Strominger JL, Siebold C. MHC class II proteins and disease: a structural perspective. Nat Rev Immunol. 2006;6(4):271-282.
37. Ovsyannikova IG, Jacobson RM, Ryan JE, et al. HLA class II alleles and measles virus-specific cytokine immune response following two doses of measles vaccine. Immunogen. 2005;56(11):798-807. (Pubitemid 40558083)
38. Ovsyannikova IG, Ryan JE, Jacobson RM, Vierkant RA, Pankratz VS, Poland GA. Human leukocyte antigen and interleukin 2, 10 an d12p40 cytokine responses to measles: Is there evidence of the HLA effect? Cytokine. 2006;36(3-4):173-179. (Pubitemid 46275467)
39. Skinnider BF, Mak TW. The role of cytokines in classical Hodgkin lymphoma. Blood. 2002;99(12):4283-4297. (Pubitemid 34627193)
40. Jarrett RF. Risk factors for Hodgkin's lymphoma by EBV status and significance of detection of EBV genomes in serum of patients with EBV-associated Hodgkin's lymphoma. Leuk Lymphoma. 2003;44(suppl 3):S27-S32.